MSM (methylsulfonylmethane)
Also called: methylsulfonylmethane, methyl sulfonyl methane, dimethyl sulfone, sulfonylbismethane
Methylsulfonylmethane (MSM), proper name dimethyl sulfone, is a sulfur-containing compound present in small amounts in many foods. Health Canada lists supplement MSM as synthetic. It is used as a single agent and in combination with other nutrients.
- Category
- Other
- Forms
- Methylsulfonylmethane (dimethyl sulfone), synthetic, in oral capsules, tablets and powders
- Strongest evidence
- B Some positive trials
- Reviewed
- 2026-10-30
Class 1 Well studied in people. Ten randomized placebo-controlled trials of oral MSM alone were opened on PubMed (2026-10-30): knee osteoarthritis or knee pain (5), low back pain (1), exercise (3) and blood lipids (1). No review stating a pooled MSM trial count was found. [2]
Fact-checked 2026-10-30 · How this guide is made
Education, not medical advice. These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure or prevent any disease, or to replace any medication or medical advice. EUTECNIQ sells no supplements today, and this page links to no product. Supplements can interact with medicines; ask a doctor or pharmacist before use, especially in pregnancy, while breastfeeding, before surgery or for a child.
What research has studied
Grades describe the human evidence in the cited sources, not a recommendation. A means consistent randomized trials; X means good trials found no effect.
BBones and joints3 topics
CHeart and blood vessels1 topic
CMuscles and exercise1 topic
CSkin and hair1 topic
A consistent trialsB some positive trialsC limited human evidenceD lab or animal onlyX no effect in good trials
| Topic studied | Grade | What the evidence shows |
|---|---|---|
| Knee osteoarthritis pain and function | B | A 2018 meta-analysis of placebo-controlled RCTs of oral supplements found statistically significant improvements in osteoarthritis pain with MSM, but of unclear clinical importance. [12] |
| Knee pain during military training | C | In an RCT of 180 military trainees, 3 g/day for 8 weeks did not significantly improve knee outcome or mood scores versus placebo. [6] |
| Mild knee pain in healthy adults | C | In an RCT of 88 healthy Japanese adults with mild knee pain, 2 g/day (ten 200 mg tablets) for 12 weeks improved a knee quality-of-life score versus placebo (p = 0.046). [5] |
| Exercise-induced muscle damage, oxidative stress and pain | C | In an RCT of 22 half-marathon runners, 3 g/day did not reduce oxidative-stress or muscle-damage markers; muscle and joint pain fell by clinically meaningful amounts that were not statistically significant. [7] |
| Blood lipids in overweight and obese adults | C | In an RCT of 22 overweight or obese adults, 3 g/day MSM for 16 weeks raised HDL cholesterol at 8 and 16 weeks compared with baseline. [10] |
| Facial wrinkles and skin texture | C | In a 16-week pilot of 20 participants, 3 g/day MSM reduced facial wrinkles and skin roughness versus placebo; a second part compared 1 g and 3 g/day without a placebo group. [13] |
Main constituents: Dimethyl sulfone (methylsulfonylmethane), an organosulfur compound [13]
Amounts studied and limits
Amounts used in research, not dosing advice. Products differ in form and strength; a clinician can advise on an individual dose.
- Knee osteoarthritis pilot RCT: MSM 3 g twice a day (6 g/day) for 12 weeks. [2]
- Knee osteoarthritis RCT: 1.125 g three times daily for 12 weeks. [3]
- Knee osteoarthritis RCT: 500 mg three times daily for 12 weeks (MSM-alone arm). [4]
- Low back pain RCT safety analysis: 6 g/day for 16 weeks. [11]
- Health Canada's MSM monograph (December 19, 2025), adults: 1,500–6,000 mg per day, not to exceed 2,000 mg per single dose, for at least 4 weeks; at 1,500 mg/day or more, take with food and avoid taking at bedtime. [1]
No official upper intake level has been set.
Safety and side effects
- Liver (NIH LiverTox)See details
In a randomized, placebo-controlled low back pain trial, 6 g/day MSM for 16 weeks had no effect on total bilirubin, ALT or AST compared with placebo.
Details and sources - Pregnancy and breastfeedingHealth Canada's MSM monograph requires the label caution to ask a health care practitioner before use if pregnant or breastfeeding.
1 statement in the profile.
Details and sources - Interactions with medicinesNothing found
No published information found in the sources checked.
Details and sources - Cancer evaluations (IARC, NTP)None found
No IARC or NTP evaluation was found in the lists checked. The profile notes other test results.
Details and sources - FDA new dietary ingredient notificationsNone on FDA's list
FDA does not approve dietary supplements. Each entry is one party's filing.
Details and sources - Dose in official monographsStated
Health Canada NNHPD MSM monograph (December 19, 2025), adults 18 years and older: 1,500–6,000 mg of MSM per day, not to exceed 2,000 mg per single …
Details and sources
- Health Canada lists gastrointestinal discomfort or disturbances as a known adverse reaction and requires a caution to ask a health care practitioner before use if pregnant or breastfeeding. [1]
- In a randomized, placebo-controlled trial, 6 g/day for 16 weeks had no effects on white blood cells, platelets, hemoglobin, glucose, bilirubin, ALT or AST compared with placebo. [11]
- In the 2006 knee osteoarthritis pilot RCT, 6 g/day for 12 weeks produced no major adverse events; the authors state long-term safety cannot be confirmed from that trial. [2]
Regulatory status
- US: FDA had no questions about GRAS Notice 229 for methylsulfonylmethane in meal supplement and meal replacement foods, certain beverages (up to 4,000 mg/kg) and food bars (up to 30,000 mg/kg) (closed February 18, 2008). [14]
- US: no NDI notification naming methylsulfonylmethane or MSM was found in FDA's published NDI list (dated July 9, 2026; checked 2026-10-30). [16]
- US: under DSHEA, FDA does not have the authority to approve dietary supplements before they are marketed; firms are responsible for ensuring their products are not adulterated or misbranded. [15]
- Canada: Health Canada publishes an MSM monograph (December 19, 2025) for licensed natural health products to help relieve joint pain associated with osteoarthritis of the knee. [1]
Safety, quality and supply profile
Fourteen questions a careful buyer, formulator or clinician would ask, each answered only from a cited source (checked 2026-10-30). If our sources do not answer a question, we say so.
Compounds responsible
Compounds the sources name as the main or characteristic actives.
- Methylsulfonylmethane (proper name dimethyl sulfone; also sulfonylbismethane), listed by Health Canada as synthetic Organosulfur compounds (sulfone) [P1]
US status
What FDA's published records show. FDA does not approve dietary supplements.
- No NDI notification naming methylsulfonylmethane or MSM was found in FDA's published NDI list (dated July 9, 2026; checked 2026-10-30). FDA keeps no authoritative list of ingredients marketed before October 15, 1994. [P2]
- FDA had no questions about GRAS Notice 229 for methylsulfonylmethane as an ingredient in meal supplement and meal replacement foods, fruit smoothie-type drinks and fruit-flavored thirst quencher-type beverages at up to 4,000 mg/kg, and food bars at up to 30,000 mg/kg (closed February 18, 2008; additional correspondence on a specification change February 27, 2017). [P3]
Cancer evaluations (IARC and NTP)
Evaluations name the exact material tested, which may differ from a supplement.
- No IARC or NTP carcinogenicity evaluation of methylsulfonylmethane (dimethyl sulfone) was found (IARC Monographs cumulative cross index, Volumes 1 to 142, and NTP technical reports index TR-001 to TR-606, checked 2026-10-30). [P4]
- The NTP Technical Reports index lists no 2-year study of methylsulfonylmethane (checked 2026-10-30). [P5]
Liver (NIH LiverTox)
- In a randomized, placebo-controlled low back pain trial, 6 g/day MSM for 16 weeks had no effect on total bilirubin, ALT or AST compared with placebo. [P6]
Interactions with medicines
- No published information found in the sources checked.
Alcohol
- No published information found in the sources checked.
Interactions with other herbs and supplements
- No published information found in the sources checked.
Adulteration and substitution
- No published information found in the sources checked.
What a certificate of analysis should cover
Tests a quality specification for this material would include, with the reason for each.
- Identity: at least one appropriate test or examination to verify the identity of each component that is a dietary ingredient (21 CFR 111.75(a)(1)(i)) — General Part 111 requirement for every dietary ingredient; FDA may exempt a firm only by granting a petition under 111.75(a)(1)(ii). [P7]
Supply and conservation
- Health Canada lists the source of MSM in its monograph as synthetic. [P1]
Absorption in people
- No published information found in the sources checked.
Formulations studied to change absorption
Human data only.
- No published information found in the sources checked.
Dose in official monographs
As the monograph states it, for its jurisdiction; not personal advice.
- Health Canada NNHPD MSM monograph (December 19, 2025), adults 18 years and older: 1,500–6,000 mg of MSM per day, not to exceed 2,000 mg per single dose; use for at least 4 weeks; products providing 1,500 mg or more per day: take with food and avoid taking at bedtime. [P1]
Pregnancy and breastfeeding
- Health Canada's MSM monograph requires the label caution to ask a health care practitioner before use if pregnant or breastfeeding. [P1]
Sources for this profile
- Health Canada NNHPD. Natural health product monograph: MSM (date December 19, 2025), 2025-12-19. webprod.hc-sc.gc.ca
- FDA. Submitted 75-Day Premarket Notifications for New Dietary Ingredients (list dated July 9, 2026), 2026-07-09. fda.gov
- FDA. GRAS Notice Inventory: GRN No. 229, Methylsulfonylmethane (closed Feb 18, 2008; additional correspondence Feb 27, 2017), 2008-02-18. hfpappexternal.fda.gov
- IARC Monographs. Cumulative Cross Index to IARC Monographs Volumes 1 to 142 (PDF, retrieved 2026-10-30), 2026-10-30. monographs.iarc.who.int
- National Toxicology Program. Technical Reports (TR series index, TR-001 to TR-606), 2026-10-30. ntp.niehs.nih.gov
- Crawford P, et al. Methylsulfonylmethane for treatment of low back pain: a safety analysis of a randomized, controlled trial. Complement Ther Med 2019;45:85-88 (PMID 31331587), 2019-08. pubmed.ncbi.nlm.nih.gov
- eCFR. 21 CFR 111.75, What must you do to determine whether specifications are met? (up to date as of 10/29/2026), 2026-10-29. ecfr.gov
Sources
- Health Canada NNHPD. Natural health product monograph: MSM (date December 19, 2025), 2025-12-19. webprod.hc-sc.gc.ca
- Kim LS, et al. Efficacy of methylsulfonylmethane (MSM) in osteoarthritis pain of the knee: a pilot clinical trial. Osteoarthritis Cartilage 2006;14(3):286-294 (PMID 16309928), 2006-03. pubmed.ncbi.nlm.nih.gov
- Debbi EM, et al. Efficacy of methylsulfonylmethane supplementation on osteoarthritis of the knee: a randomized controlled study. BMC Complement Altern Med 2011;11:50 (PMID 21708034), 2011-06-27. pubmed.ncbi.nlm.nih.gov
- Usha PR, Naidu MU. Randomised, double-blind, parallel, placebo-controlled study of oral glucosamine, methylsulfonylmethane and their combination in osteoarthritis. Clin Drug Investig 2004;24(6):353-363 (PMID 17516722), 2004. pubmed.ncbi.nlm.nih.gov
- Toguchi A, et al. Methylsulfonylmethane improves knee quality of life in participants with mild knee pain: a randomized, double-blind, placebo-controlled trial. Nutrients 2023;15(13):2995 (PMID 37447322), 2023-06-30. pubmed.ncbi.nlm.nih.gov
- Tennent DJ, et al. A randomized controlled trial evaluating methylsulfonylmethane versus placebo to prevent knee pain in military initial entry trainees. US Army Med Dep J 2017;(3-17):21-25 (PMID 29214616), 2017-10. pubmed.ncbi.nlm.nih.gov
- Withee ED, et al. Effects of methylsulfonylmethane (MSM) on exercise-induced oxidative stress, muscle damage, and pain following a half-marathon: a double-blind, randomized, placebo-controlled trial. J Int Soc Sports Nutr 2017;14:24 (PMID 28736511), 2017-07-21. pubmed.ncbi.nlm.nih.gov
- Barmaki S, et al. Effect of methylsulfonylmethane supplementation on exercise-induced muscle damage and total antioxidant capacity. J Sports Med Phys Fitness 2012;52(2):170-174 (PMID 22525653), 2012-04. pubmed.ncbi.nlm.nih.gov
- Nakhostin-Roohi B, et al. Effect of single dose administration of methylsulfonylmethane on oxidative stress following acute exhaustive exercise. Iran J Pharm Res 2013;12(4):845-853 (PMID 24523764), 2013. pubmed.ncbi.nlm.nih.gov
- Miller L, et al. The effect of daily methylsulfonylmethane (MSM) consumption on high-density lipoprotein cholesterol in healthy overweight and obese adults: a randomized controlled trial. Nutrients 2021;13(10):3620 (PMID 34684621), 2021-10-15. pubmed.ncbi.nlm.nih.gov
- Crawford P, et al. Methylsulfonylmethane for treatment of low back pain: a safety analysis of a randomized, controlled trial. Complement Ther Med 2019;45:85-88 (PMID 31331587), 2019-08. pubmed.ncbi.nlm.nih.gov
- Liu X, et al. Dietary supplements for treating osteoarthritis: a systematic review and meta-analysis. Br J Sports Med 2018;52(3):167-175 (PMID 29018060), 2018-02. pubmed.ncbi.nlm.nih.gov
- Muizzuddin N, Benjamin R. Beauty from within: oral administration of a sulfur-containing supplement methylsulfonylmethane improves signs of skin aging. Int J Vitam Nutr Res 2022;92(3-4):182-191 (PMID 32083522), 2022-07. pubmed.ncbi.nlm.nih.gov
- FDA. GRAS Notice Inventory: GRN No. 229, Methylsulfonylmethane (closed Feb 18, 2008; additional correspondence Feb 27, 2017), 2008-02-18. hfpappexternal.fda.gov
- U.S. Food and Drug Administration. Questions and Answers on Dietary Supplements (Content current as of 08/27/2026), 2026-08-27. fda.gov
- FDA. Submitted 75-Day Premarket Notifications for New Dietary Ingredients (list dated July 9, 2026), 2026-07-09. fda.gov
- A
- Consistent results from several randomized trials or a systematic review of them
- B
- Some positive randomized trials, but small, short, few or inconsistent
- C
- Limited human evidence: single small trials, observational data or mixed results
- D
- Laboratory or animal evidence only; not shown in people
- X
- Well-designed human trials found no meaningful effect
More in this category: Alpha-lipoic acid · Bee pollen · Beetroot juice (dietary nitrate) · Berberine · Beta-glucan (oat and barley) · Betaine (trimethylglycine) · Bromelain · Caffeine · All entries A–Z · How to judge a supplement
Health information notice
These statements have not been evaluated by the Food and Drug Administration. Nothing on this site is intended to diagnose, treat, cure or prevent any disease. The information is for general education only. It is not medical advice and does not replace advice, diagnosis or treatment from a qualified health professional, or any medication a clinician has prescribed.
Do not start, stop or change any medicine, supplement or herbal product because of something you read here. Talk to your doctor or pharmacist first, especially if you are pregnant or breastfeeding, have a medical condition, take any medicines, are preparing for surgery, or are caring for a child. Research findings, traditional uses and safety data are reported as their sources state them; they are not recommendations or claims about any product. If you think you may have a medical emergency, call your doctor or 911 at once.
EUTECNIQ Sciences sells no supplements or health products today and receives nothing from any product or ingredient mentioned on this site; any commercial interest it later has in an ingredient will be stated on that ingredient’s page.